|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||73.74 - 74.92|
|52 Week Range||73.74 - 94.67|
|PE Ratio (TTM)||19.69|
|Earnings Date||Apr 24, 2018 - Apr 30, 2018|
|Forward Dividend & Yield||2.87 (3.65%)|
|1y Target Est||90.65|
Procter & Gamble (PG) continued to report sluggish margins in fiscal 3Q18. The company’s core gross margin fell 110 basis points to 49.4% in fiscal 3Q18 as lower pricing to drive volumes and increased cost pressure more than offset the benefits stemming from cost and productivity savings.
Lower pricing adversely impacted Procter & Gamble’s (PG) sales across product segments amid increased competitive activity. However, favorable currency rates and improved volumes drove top-line growth.
The Consumer Staples Select Sector SPDR ETF (XLP)—a basket of 34 companies in the sector—lost almost 3% Thursday, largely caused by the 16% drop in tobacco giant Philip Morris (PM), after its cigarette shipments fell more than expected and its heated-tobacco product—an area with high expectations for rapid growth—was experiencing headwinds in key market Japan. The company cited higher commodities and transportation costs as the cause of narrower margins, and admitted sales growth "has been challenging in a very difficult market environment." These three companies collectively comprise approximately 25% of the consumer-staples sector, which helps explain why the Consumer Staples ETF dropped 4.1% last week. It's no secret that Amazon.com (AMZN) and Walmart (WMT) have essentially made the retail space an oligopoly, says Mike O’Rourke, chief market strategist of JonesTrading.
Procter & Gamble (PG) reported net sales of $16.3 billion, a rise of 4.3% YoY (year-over-year), which exceeded analysts’ expectations. As expected, Procter & Gamble’s top line benefitted from improved volumes and favorable currency rates. Also, the improved mix contributed 1% to the net sales growth rate.
Procter & Gamble (PG) reported adjusted earnings of $1.00 per share in fiscal 3Q18, which came in ahead of analysts’ estimate of $0.98 and increased 4.2% YoY (year-over-year). Moreover, Procter & Gamble has now surpassed analysts’ earnings expectations in the past 12 quarters. However, what didn’t sit well with investors was the company’s low EPS growth rate, especially given the benefits from favorable currency rates, the low tax rate environment, and strong productivity savings.
Shares of Procter & Gamble (PG) are tumbling Friday, a day after it reported lackluster organic sales growth guidance, which overshadowed slightly better than expected third-quarter earnings. Argus’ John Staszak downgraded the shares to Hold from Buy, writing that the company’s growth has not increased to the level he expected despite divestitures. Deutsche Bank's Stephen Powers downgraded P&G to Hold from Buy and lowered his price target to $80 from $88.
Goldman Sachs reported first-quarter results that handily beat on both the top and bottom lines, but its stock fell 1.6 percent after the financial report. Consumer giant Procter & Gamble may have faced a similar issue after it reported strong revenues on Thursday. "It's not the earnings beat, look at the revisions, it's the direction of the estimates that move prices," Nick Raich of The Earnings Scout said.
Companies have been crushing earnings so far this quarter, but a strange trend is developing: Those that beat expectations are seeing their stock price fall.
Better-than-expected results and a big-ticket acquisition could not save Procter & Gamble stock. Time to stave off from staples ETFs?
Procter & Gamble (PG) reported weak sales and earnings growth in fiscal 3Q18 (period ended March 31, 2018) on April 19, 2018. The company’s stock fell 4.2% after the release and closed at $74.95. Procter & Gamble’s soft organic sales and tepid margin performance sent the stocks of other major CPG (consumer packaged goods) companies down as investors fear that price competition, business reinvestment needs, and inflation in commodities and transportation costs are likely to dent the financials of these companies.
Procter & Gamble Co. has launched an advertising campaign featuring TV and movie star Priyanka Chopra, and the brand ambassador for Pantene shampoo suggests people think twice about making harsh social media posts.
Procter & Gamble Co. began notifying brand teams this week that they can resume advertising on YouTube, the video-sharing website that’s a subsidiary of Google.
Procter & Gamble Co (NYSE: PG ) reported fiscal third-quarter earnings Thursday that exceeded the Street's expectations but also reaffirmed disappointing organic growth rates, according to Argus. The Analyst ...
Bank of America Merrill Lynch analysts downgraded Procter & Gamble to neutral from buy and cut their price target on the stock by $8 to $82 a share. The report cited negative price pressures in every segment for the latest quarter, a disproportionate hit to the company from industry destocking and rising costs for consumer packaged goods companies. Bank of America Merrill Lynch downgraded P PG rocter & Gamble PG to neutral from buy, based on the view it will be more difficult than expected for the business to grow.
Bank of America Merrill Lynch downgraded Procter & Gamble to neutral from buy, based on the view it will be more difficult than expected for the business to grow.
Most of the analysts covering Colgate-Palmolive (CL) have maintained “hold” ratings on its stock as a soft sales environment, a moderating category growth rate, increased competition, and margin headwinds have kept them on the sidelines.
Moody's Investors Service, ("Moody's") today affirmed the ratings of The Procter & Gamble Company ("P&G"), including its Aa3 senior unsecured rating and Prime-1 short-term rating. This ...
NEW YORK, NY / ACCESSWIRE / April 20, 2018 / The Clorox Company and Procter & Gamble both sank to new lows on Thursday. The Clorox company saw its shares decrease after a downgrade from a Morgan Stanley ...
As for Colgate-Palmolive (CL), the company’s profit margins are likely to be adversely impacted by inflation in commodity prices, including resins and pulp. Higher logistics costs and increased advertising spending to support new product launches and drive market share are also expected to hurt its margins. Higher volumes, a focus on productivity savings, and SKU optimization are likely to support its margins.
Procter & Gamble, which is buying the Merck unit, was previously reported to be in talks to acquire Pfizer's consumer healthcare business.